# Seres Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Seres Therapeutics, Inc.). ## Overview Seres Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing live biotherapeutic product candidates. Its pipeline includes SER-155, SER-603, and SER-147, and its operations are centered on microbiome-based therapies and related manufacturing capabilities in Cambridge, Massachusetts. ## Products & services • SER-155 live biotherapeutic candidate • SER-603 live biotherapeutic candidate • SER-147 live biotherapeutic candidate • Microbiome-based drug discovery platform • cGMP manufacturing for clinical supply • Contract manufacturing and testing support - **Clinical-stage live biotherapeutic candidates** (70%) — Pipeline LBP programs being developed for infectious, inflammatory, and immune-related diseases. - **Microbiome discovery platform** (10%) — Human-data-driven discovery capabilities used to identify and advance new LBP candidates. - **Manufacturing and development services** (20%) — Internal cGMP manufacturing and related support for drug substance and drug product. - SER-155 live biotherapeutic candidate - SER-603 live biotherapeutic candidate - SER-147 live biotherapeutic candidate - Microbiome-based drug discovery platform - cGMP manufacturing for clinical supply - Contract manufacturing and testing support ## Customers Seres does not currently sell approved products broadly; its economic relationships are primarily with collaborators, development partners, and contract counterparties that support research, manufacturing, and transition services. If its pipeline advances, its eventual customers would include hospitals, physicians, and payors involved in treatment decisions for medically vulnerable patient populations. - **Collaborators and strategic partners** (primary) — They support development, transition services, and other contractual arrangements tied to pipeline programs. - **Clinical and research organizations** (primary) — CROs, CMOs, and testing labs that buy or provide development and manufacturing support. - **Hospitals and transplant centers** (secondary) — Potential future users of approved therapies such as SER-155 in transplant settings. - **Physicians and healthcare providers** (secondary) — Prescribers who would recommend any approved product in medically vulnerable populations. - **Third-party payors** (secondary) — Insurers and government programs that would determine coverage and reimbursement. - Collaborators that fund or support development programs - Contract manufacturers and testing partners - Hospitals and transplant centers for future clinical use - Physicians treating medically vulnerable patient groups - Government and private payors for reimbursed therapies ## Geography Seres is headquartered and manufactures in the United States, with cGMP operations in Cambridge, Massachusetts. Its business is primarily U.S.-based today, while its intellectual property, collaboration rights, and future commercialization potential may extend to other markets. - **United States** (100%) — Company operations and manufacturing are U.S.-based; no country revenue disclosure provided. - Headquartered in the United States - cGMP manufacturing in Cambridge, Massachusetts - Current operations are concentrated in U.S. R&D - Future commercialization could extend beyond the U.S. - IP and licensing rights may have worldwide scope ## Strategy Seres is focused on advancing SER-155 and its other wholly owned live biotherapeutic candidates through clinical development and regulatory review. It is also preserving manufacturing capability, intellectual property, and collaboration flexibility so it can support future commercialization if a candidate is approved. - **Advance SER-155 clinical development** (short-term) — SER-155 is the lead remaining program and the main near-term value driver. - **Build manufacturing capability** (medium-term) — Live biotherapeutics require specialized cGMP production and supply control. - **Protect and expand IP** (medium-term) — Patent and know-how protection are central to differentiation in microbiome therapeutics. - **Prepare for future commercialization** (long-term) — Any approved product would require sales, distribution, and reimbursement infrastructure. - Advance SER-155 in allo-HSCT and other vulnerable populations - Progress SER-603 and other early pipeline assets - Invest in manufacturing capabilities for clinical and future supply - Maintain and expand proprietary live biotherapeutic know-how - Seek regulatory approvals and future commercialization readiness ## Risks Seres faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delay, and the need for additional capital before product sales are established. Its concentration in a smaller number of live biotherapeutic programs also increases exposure to scientific, manufacturing, and competitive setbacks. - **Need for additional capital** [critical] — Development and commercialization require funding before product revenue exists. - **Clinical development failure** [high] — Pipeline value depends on positive trial outcomes and acceptable safety. - **Regulatory approval delay or denial** [high] — LBPs must clear FDA review and may face evolving regulatory expectations. - **Manufacturing and supply complexity** [medium] — Live biotherapeutics require controlled cultivation, testing, and cGMP processes. - **Competition from larger biopharma companies** [medium] — Competitors may have more resources and faster development timelines. - Clinical trial failure or safety issues could halt programs - Additional capital may be needed before product sales - Regulatory approval is uncertain and time-consuming - Competition from larger biotech and pharma firms is intense - Manufacturing scale-up for live biotherapeutics is complex ## Accounting Seres’ reported results are shaped by collaboration revenue, research and development accruals, and estimates tied to transition-service and manufacturing arrangements. The sale of the VOWST business created discontinued-operations accounting, while stock-based compensation, warrant liabilities, and accrued R&D expenses can materially affect period-to-period comparability. - **Collaboration and milestone revenue** — Can create uneven quarterly revenue recognition - **Discontinued operations** — Affects trend analysis and segment comparability - **Accrued research and development expenses** — Can shift reported R&D expense between periods - **Warrant liabilities and fair value changes** — Can add non-operating volatility to reported results - **Stock-based compensation** — Impacts operating loss and expense comparability - Collaboration revenue depends on contract terms and milestone timing - Discontinued-operations accounting affects comparability after the VOWST sale - Accrued R&D expenses rely on estimates for CRO and CMO work - Warrant liabilities can create fair-value volatility - Stock-based compensation affects operating expense trends --- *Last updated: 2026-04-29T04:58:08.295179+00:00*